Pharvaris BV (PHVS) - Total Liabilities
Based on the latest financial reports, Pharvaris BV (PHVS) has total liabilities worth $27.86 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Pharvaris BV (PHVS) asset resilience to evaluate the company's liquid asset resilience ratio.
Pharvaris BV - Total Liabilities Trend (2017–2025)
This chart illustrates how Pharvaris BV's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see PHVS total asset value.
Pharvaris BV Competitors by Total Liabilities
The table below lists competitors of Pharvaris BV ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Capri Global Capital Limited
NSE:CGCL
|
India | Rs254.73 Billion |
|
JTC PLC LS-01
F:2N9
|
Germany | €555.23 Million |
|
Autobio Diagnostics Co Ltd
SHG:603658
|
China | CN¥2.99 Billion |
|
First Bancorp
NASDAQ:FBNC
|
USA | $11.33 Billion |
|
Boise Cascad Llc
NYSE:BCC
|
USA | $1.36 Billion |
|
Acer Incorporated
F:AC5G
|
Germany | €147.16 Billion |
|
Kenon Holdings
TA:KEN
|
Israel | ILA3.82 Billion |
|
Hyundai Mar&Fi
KO:001450
|
Korea | ₩43.91 Trillion |
Liability Composition Analysis (2017–2025)
This chart breaks down Pharvaris BV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Pharvaris BV (PHVS) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pharvaris BV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pharvaris BV (2017–2025)
The table below shows the annual total liabilities of Pharvaris BV from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $30.18 Million | +27.81% |
| 2024-12-31 | $23.61 Million | +61.23% |
| 2023-12-31 | $14.65 Million | -20.72% |
| 2022-12-31 | $18.47 Million | +158.85% |
| 2021-12-31 | $7.14 Million | +34.31% |
| 2020-12-31 | $5.31 Million | +176.17% |
| 2019-12-31 | $1.92 Million | +299.74% |
| 2018-12-31 | $481.34K | +246.70% |
| 2017-12-31 | $138.84K | -- |
About Pharvaris BV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and a… Read more